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1. Introduction
Protein glycosylation is an important posttranslational modification that confers both struc‐
tural and functional properties to the molecules [1]. There are several types of glycosylation
with various carbohydrate structures, and biosynthesis of each sugar chain, in general, is an
elaborate process of addition and processing of carbohydrates in the endoplasmic reticulum
(ER) and Golgi, where a number of glycosyltransferases and glycosidases are involved in
these reactions. Glycoprotein degradation, on the other hand, requires many hydrolases to
act on carbohydrates and involves intracellular transport of both glycosidases and their sub‐
strate glycoproteins. Collectively, enzymes that modulate glycoprotein carbohydrates dur‐
ing their biosynthesis and degradation are called glycoenzymes, which play critical roles in
maintaining cellular structure and function. Biosynthesis of carbohydrate moieties of glyco‐
proteins, unlike that of DNA, RNA, or proteins, is a template-independent reaction, that is,
their structures are not directly encoded by genes. However, they reflect biochemical reac‐
tions catalyzed by glycoenzymes expressed in a cell. In other words, structural integrity of
carbohydrates is indirectly determined by a large number of genes coding for glycoen‐
zymes. Therefore, mutations in any of these enzymes that affect the structures and functions
of glycoproteins will cause deleterious effects on cellular activities.
Glycosylation is categorized into 2 major classes on the basis of the linkage structure be‐
tween a polypeptide and a carbohydrate chain, i.e., N-linked and O-linked oligosaccharides
(Fig. 1). N-Linked glycans, the most extensively studied class, are the ones attached to an
asparagine (Asn) residue in the Asn-X-Ser/Thr triplet sequence (X, any amino acid except
proline; Ser, serine; Thr, threonine) in a polypeptide chain. Glycans that are attached to a hy‐
droxylamino acid residue are called O-linked oligosaccharides and can be categorized into
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several subclasses, according to the types of monosaccharides directly attached to the amino
acid (Fig. 1). Among them, O-GalNAc and O-Xyl are the most frequently observed modifica‐
tions in mucins and proteoglycans, respectively; therefore, the former oligosaccharides are
also called mucin-type glycans. In addition, novel types of O-glycosylation, including O-Fuc
and O-Man, were recently identified and suggested to be involved in the regulation of es‐
sential proteins, such as notch, dystroglycan, etc. [2,3]. Since these carbohydrate chains have
characteristic structures and play critical roles in cellular functions, their alterations have
been found to be associated with a number of inherited diseases.
In this article, diseases that are associated with altered protein glycosylation are described.
Moreover, to achieve the normal cellular function, glycoenzymes involved in glycosylation
processes such as synthesis, processing, and degradation must be under the proper control.
Important roles of some of these enzymes are also discussed, with a focus especially on
those modulating N-Asn-, O-Man-, and O-GalNAc-type oligosaccharides.
 
 
Figure 1. Classification of glycoprotein carbohydrate chains.
2. N-glycan biosynthesis
2.1. Glycoenzymes involved in N-glycan biosynthesis
N-Glycans are characterized by a linkage structure of GlcNAcβ1Asn. Its biosynthesis is dis‐
tinct from that of other glycans in that a precursor oligosaccharide preassembled on a lipid
dolichol (Dol) is en block transferred to a polypeptide chain that is being translated in the ER
(Fig. 2). Consecutive addition of sugars onto dolichyl-phosphate gives rise to the final pre‐
cursor product, Glc3Man9GlcNAc2-P-P-Dol. The completed glycan is then transferred to a
nascent polypeptide with an essential Asn-X-Ser/Thr sequence in the ER lumen, which is
catalyzed by an oligosaccharyltransferase. Following transfer to polypeptides, N-glycans are
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usually processed during intracellular transport of glycoprotein (Fig. 2). In the ER, glucosi‐
dases I and II remove the outermost α1,2-linked and 2 inner α1,3-linked glucose residues.
The outermost α1,2-linked mannose is then released by ER α-mannosidase to generate
Man8GlcNAc2-Asn. After transit to cis-Golgi, mannosidases remove 3 mannose residues,
thereby producing Man5GlcNAc2-Asn, a substrate for GlcNAc-transferase I that adds a
GlcNAc residue to the α1,3-linked Man. Subsequent removal of 2 mannose residues on the
α1,6-linked Man occurs, and the second GlcNAc is added on the non-reducing mannose res‐
idues. Final addition of galactose and sialic acid residues completes biantennary complex-
type N-glycans. It should be noted that additional GlcNAc-transferases can make 5 or more
branched complex-type sugar chains. The branched structures in most cases are modified by
consecutive addition of galactose and sialic acid residues, such that a variety of N-glycans
can be generated by a series of actions of glycosidases and glycosyltransferases. Therefore,
mutations of these enzymes would potentially result in production and accumulation of un‐
usual oligosaccharides in the cell.
Figure 2. Biosynthesis and processing of N-linked oligosaccharides.
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2.2. Disorders in N-glycan biosynthesis: CDG-I and CDG-II
Congenital disorders of glycosylation (CDG), previously known as carbohydrate-deficient
glycoprotein syndrome, are a subset of genetic diseases characterized by abnormalities in
glycosylation. N-Glycans are physiologically and developmentally important in various tis‐
sues, and therefore the complete absence of these oligosaccharides is lethal. Almost all
CDGs are autosomal recessive; patients carrying hypomorphic mutant alleles exhibit multi‐
ple organ failure, such as neurodevelopmental disorders, hepatopathy, and immunological
diseases. Since the biosynthesis of N-glycans consists of 2 distinct processes (i.e., the assem‐
bly of precursor oligosaccharides on dolichol and the processing of oligosaccharides after
transfer to acceptor proteins), CDGs can be categorized into 2 general types. One type is
caused by insufficient assembly of the lipid-linked precursor oligosaccharides in the ER,
which is characterized by decreases in the number of N-glycans with normal structures. The
other type involves defects in the processing of oligosaccharides that are transferred to pro‐
teins, thereby resulting in the production of short and simple sugar chains without affecting
the number of glycans. The former type, designated as CDG-I, constitutes defects in the syn‐
thesis of dolichol lipid-linked oligosaccharide (LLO) chain as well as its transfer to proteins
in the ER. The first report on CDG was made in 1980 [4], and 15 years later, it was proposed
that the disease, CDG-Ia, is caused by the deficiency of an enzyme, phosphomannomutase
[5]. This enzyme catalyzes the interconversion of mannose 6-phosphate and mannose 1-
phosphate (Fig. 2), and its deficiency leads to a shortage of substrates (GDP-Man and Dol-P-
Man) that are required for the synthesis of dolichol-oligosaccharides. CDG-Ia is the most
common CDG, and its frequency has been estimated as 1 in 20,000 live births. A less com‐
mon type of CDG, CDG-1b, possesses deficiency in phosphomannose isomerase (Fig. 2)
[6,7]. Without this enzyme, the cells fail to convert fructose 6-phosphate to mannose 6-phos‐
phate and, similarly to CDG-Ia, cannot generate LLOs efficiently. Interestingly, it was found
that treating patients with CDG-Ib, but not CDG-Ia, with high-mannose diet alleviates the
clinical manifestation, since mannose 6-phospahte can be produced by hexokinase from
mannose ingested from food [7]. To date, there are several different types of CDG-I, all of
which are due to genetic defects in enzymes involved in the generation of LLOs. CDG-II, on
the other hand, involves malfunctions in the trimming or processing of the protein-bound
chains in the ER and Golgi. For example, CDG-IIa is caused by mutations in N-acetylgluco‐
saminyltransferase II (GlcNAc-TII), which adds the second GlcNAc residue to biantennary
complex glycans (Fig. 2) [8]. β1,4-Galactosyltransferase, the enzyme that adds galactose after
GlcNAc-TII, is mutated in CDG-IId (Fig. 2) [9]. Failure in sialylation of biantennary complex
chains (Fig. 2), which results from a defect in the CMP-Sia transporter, is observed in CDG-
IIf [10]. CDG-IIa, -IId, and -IIf cannot produce complex-type carbohydrates and exhibit se‐
vere phenotypes, such as mental retardation, hypotonia, and neutropenia. In addition to
these examples, CDG-II patients also have diverse disorders that result from mutations in
other glycosyltransferases and nucleotide sugar transporters. Moreover, there are other
types of N-glycosylation disorders, including mucolipidosis II (MLII), alternatively called as
I-Cell disease, caused by the lack of mannose 6-phosphate, which serve as a molecular tag to
direct transport to lysosomes (Fig. 2) [11].
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3. O-glycan biosynthesis
As shown in Fig. 1, there are several subclasses of O-glycosylation, and each subclass has its
own biosynthetic process with specific glycosyltransferases. Disorders associated with al‐
tered O-Man and O-GalNAc glycans are described below.
3.1. Deficiency in O-mannosylation: congenital muscular dystrophies and
dystroglycopathies
O-Mannosylation is related to congenital muscular dystrophies with neuronal abnormalities,
such as lissencephaly and mental retardation. Muscular dystrophies are genetic diseases with
degeneration and disruption of muscle fibers, resulting in the progressive wasting of skeletal
muscles and atrophy. The dystrophin-glycoprotein complex (DGC) (Fig. 3) plays a critical role
in maintaining muscle integrity [12,13]. It contains αDG, βDG, dystrophin, and other compo‐
nents, and αDG and βDG are produced from a single polypeptide called dystrophin-associat‐
ed glycoprotein or dystroglycan [14] after its proteolytic cleavage. Mutations in the DGC
components lead to unstable complex formation, which can be a potential cause of the diseas‐
es. In fact, dystrophin has been known to be a causative gene of Duchunne-type muscular dys‐
trophy [15,16].  Moreover,  among the DGC components,  αDG is  a  peripheral  membrane
protein with a mucin-like domain, which is heavily modified with O-mannosylglycans. These
sugar chains can bind to extracellular matrix proteins, such as laminin, agrin, and perlecan,
through their laminin G domains [17]. The reduced αDG glycosylation was observed in a
mouse model of muscular dystrophies, myd, indicating that its hypoglycosylation might be a
causal factor for the disorders [18,19]. Several studies demonstrated that αDG also contains
mucin-type carbohydrates, suggesting that mucin-type O-glycosylation may be involved in
the proper glycosylation of αDG [20]. As described below, other mutations also cause αDG hy‐
poglycosylation with a very wide spectrum of phenotypes [21], and all the diseases caused by
the altered αDG glycosylation have been collectively designated as dystroglycanopathies [22].
O-Mannosylation, a recently appreciated glycosylation, is predominantly observed on αDG.
Representative structures of O-mannosylglycans are described in the Fig. 3. The addition of
a mannose residue to Ser/Thr in the α-configuration is catalyzed by an enzyme complex
composed of protein O-mannosyltransferases, POMT1 and POMT2, in the ER [23]. GlcNAc
is then transferred by a protein O-mannose β1,2-N-acetylglucosaminyltransferase,
POMGnT1, in the Golgi [24]. Mutations in these enzymes result in muscular dystrophies
known as Walker–Warburg syndrome (WWS) and Muscle–Eye–Brain disease [24,25]. More‐
over, the disaccharide, GlcNAcβ1,2Manα1Ser/Thr, can be extended into a tetrasaccharide
Siaα2,3Galβ1,4GlcNAcβ1,2Manα1Ser/Thr [26]. Occurrence of sugar chains linked to the re‐
ducing mannose residue through a phosphodiester linkage has been reported [27]. Besides
POMT1, POMT2, and POMGnT1, the enzymes responsible for formation of these carbohy‐
drates have yet to be identified. While mutations in a few genes, such as fukutin, fukutin-
related protein (FKRP), and LARGE, have been suggested to cause muscular dystrophies
with the αDG hypoglycosylation, their functions are still unclear, even though they possess
features characteristic of glycosyltransferases [27-30]. Very recently, LARGE has been identi‐
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fied as a bifunctional glycosyltransferase, with both xylosyltransferase and glucuronyltrans‐
ferase activities to produce repeating units of [-Xylα1,3GlcAβ1,3-], which may be added to
the phosphodiester linkages (Fig. 3)[31]. Fukutin has also been reported to be related to the
extended structure of αDG, which is essential for the αDG binding to its ligand laminin;
however, its catalytic properties are unclear. Interestingly, while other proteins such as
CD24, IgG2 light chain, tenascin R, receptor-type protein-tyrosine phosphatase, and neuro‐
fascin [32-36] are also modified with O-mannosylglycans, αDG is most likely to be the only
molecule that is responsible for dystroglycanopathies [37].
Figure 3. Dystrophin glycoprotein complex (DGC) and representative structure of O-mannosyl glycans of αDG.
DGC components and disorders associated with their mutations are illustrated. MDC1A, Muscular dystrophy, congeni‐
tal merosin-deficient 1A (OMIM; 607855); DMD, Duchenne muscular dystrophy (OMIM; 310200); LGMD2C, Muscular
dystrophy, limb-girdle, type 2C (OMIM; 611307); LGMDC7, LGMD type C 7 (OMIM; 613818); MDDGs, Musclar dystro‐
phy-dystroglycanopathies (see ref. [22]); NOS, nitric oxide synthase.
It is important to note that only half of congenital muscular dystrophy can be explained by
gene mutations described above, suggesting that other alleles also exert effects on the phe‐
notypes [21,22,38]. The Dol-P-mannose synthase subunit DPM3 is one candidate gene; its
mutation was found in muscular dystrophy patients whose αDG glycosylation was im‐
paired [39]. Recently, mutations in the ISPD gene, which encodes isoprenoid synthase do‐
main containing, were also observed in WWS patients and are considered the second most
common cause of this disorder [40,41]. While the ISPD function in mammals is unknown, it
is involved in αDG glycosylation in zebrafish. Furthermore, a recent study suggested that
glycosyltransferase-like domain containing 2, GTDC2 or also known as AGO61, is a novel
causative gene of WWS, based on the data from whole-exome sequencing [42], even though
DG hypoglycosylation was not confirmed in patients.
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3.2. Deficiency in mucin-type O-glycosylation
3.2.1. Enzymes involved in the biosynthesis of mucin-type O-glycosylation
Biosynthesis of O-GalNAc (mucin-type) carbohydrates begins with α-GalNAc transfer from
UDP-GalNAc to a Ser/Thr residue in an acceptor polypeptide (Fig. 4). A family of UDP-Gal‐
NAc:  polypeptide N-acetylgalactosaminyltransferases  (GalNAc-Ts)  catalyzes this  reaction
predominantly in the Golgi, in contrast to the initiation of other glycosylation occurring in the
ER. GalNAc-Ts, the largest family members among glycosyltransferases with 20 isozymes in
mammals, are cis-Golgi resident enzymes, with some of which are translocated into the ER
upon signal transduction by EGF [43]. The reaction product, GalNAcα1Ser/Thr, is called the
Tn-antigen and regarded as a cancer-associated carbohydrate antigen because of its accumu‐
lation in cancer cells. Moreover, distinctive core structures (cores 1, 3, 5, 6, 7, and 8) are synthe‐
sized depending on glycosyltransferases that act on the Tn-antigen, which also appears to be
tissue-specific (Fig.4). Among these core structures, core 1 (Galβ1,3GalNAcα1Ser/Thr), also
called  the  T-antigen,  is  the  most  common  structure  and  is  generated  by  T-synthase
(C1GalT-1). This enzyme is ubiquitously expressed; however, for the proper folding and ex‐
port from the ER to Golgi, it requires a specific molecular chaperone, Cosmc. Therefore, de‐
fects  in  either  T-synthase  or  Cosmc  would  result  in  deficient  synthesis  of  T-antigens.
Furthermore, addition of β1,6-linked GlcNAc to cores 1 and 3 converts them into cores 2 and
4, respectively. Some of these core structures can also be extended into complex O-glycans fol‐
lowing modifications with galactose, N-acetylglucosamine, fucose, and sialic acid.
3.2.2. Involvement of GalNAc-T family in genetic disorders
3.2.2.1. GalNAc-T3 as a modulator of FGF23 levels
Familial tumoral calcinosis (FTC) is a rare, autosomal recessive metabolic disorder that man‐
ifests with hyperphosphatemia and massive calcium deposits in periarticular spaces, soft tis‐
sues, and sometimes in bone. The gene underlying FTC was mapped to 2q24-q31 [44] which
includes the GALNT3 gene encoding GalNAc-T3. GalNAc-T3 protects a phosphaturic factor,
FGF23, from proteolysis [45], and FGF23 inhibits the reabsorption of phosphates in proximal
renal tubule. Gain-of-function mutations in the FGF23 gene were shown to result in autoso‐
mal dominant hypophosphatemic rickets [46,47]. FGF23 secretion also requires addition of
GalNAc at Thr173 in a recognition sequence motif of subtilisin-like proprotein convertases,
which in turn blocks FGF23 proteolysis before its secretion. Therefore, mutations in
GALNT3 would result in the cleavage of intact FGF23 and lead to FTC due to accumulation
of fragmented, inactive FGF23 as well as upregulation of phosphate reabsorption.
3.2.2.2. GalNAc-T2 as a regulator of plasma lipid levels
Extensive genomic analyses recently revealed that 1q42 is associated with plasma lipid concen‐
trations [48,49], and the GALNT2 gene located in 1q42 was later found primarily associated
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with the levels of plasma high-density lipoprotein cholesterol (HDL-C). In addition, Galnt2
overexpression in mouse liver has been shown to downregulate plasma HDL-C, and knock‐
down of endogenous liver Galnt2 resulted in the opposite [50]. Moreover, apolipoprotein (apo)
C-III, identified as a candidate target protein of GalNAc-T2, inhibits lipoprotein lipase (LPL), a
hydrolase that degrades plasma triglycerides [51]. An apoC-III-based peptide is a substrate for
GalNAc-T2 while its glycosylation by the enzyme from patient is not observed. Furthermore,
neuraminidase treatment of apoC-III decreases its potential to inhibit LPL. These data suggest
that GalNAc-T2 is involved in lipid metabolism via apoC-III O-glycosylation.
Figure 4. Biosynthetic pathway of mucin-type O-glycosylation.
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3.2.2.3. GalNAc-T17 as a candidate gene for Williams–Beuren syndrome and dog domestication
Williams-Beuren syndrome (WBS) is a neurodevelopmental disorder associated with physi‐
cal, behavioral, and cognitive abnormalities [52] and is caused by haploinsufficiency of mul‐
tiple genes at 7q11.23. GalNAc-T17, also known as WBS chromosome region 17/WBSCR17
[52], was identified in the flanking region (7q11.22) of the chromosomal deletion in WBS pa‐
tients’ genome. Interestingly, WBSCR17 mRNA is predominantly expressed in the nervous
system [53]; therefore, haploinsufficiency of GalNAc-T17 can be expected to be related to
characteristic traits of WBS patients, such as hypersociality and impairment in visuospatial
processing. In addition, a recent study on the process of dog domestication reported a single
SNP located near WBSCR17 in the dog genome and has implicated WBSCR17 in the early
domestication of dogs [54]. It is also noted that GalNAc-T17 is a very inert isozyme, in terms
of catalytic activity. GalNAc-T17, together with GalNAc-T8, -T9, and -T18, belongs to the Y
subfamily, a group defined by Li et al. [55]. These Y isozymes contain several conservative
substitutions in the catalytic domain and therefore exhibit no or extremely low catalytic ac‐
tivity when tested under the standard assay conditions by using synthetic mucin peptides.
GalNAc-T17 in zebrafish, on the other hand, seems to be physiologically important, because
its knockdown resulted in embryos that exhibited malformed brain with severe alterations
in the hindbrain (ref). GalNAc-T17 has also been shown to negatively modulate macropino‐
cytosis and lamellipodium formation in cultured cells [56].
3.2.2.4. GalNAc-Ts in other genetic diseases
Recent genome-wide studies have successively revealed novel loci associated with numer‐
ous genetic diseases. Among them, some GALNT genes have been implicated in diverse dis‐
orders or tumor susceptibility: GALNT1, epithelial ovarian cancer [57]; GALNT4, acute
coronary disease [58]; GALNT11, congenital heart disease [59]; GALNT12, colon cancer [60];
GALNT13, sickle cell disease [61]; GALNT14, death-receptor mediated cancer cell death [62];
and GALNT15, colorectal cancer [63].
3.2.3. Tn syndrome caused by Cosmc mutations
The Tn syndrome is a rare autoimmune disease. In patients, subpopulations of all blood cell
lineages carry an incompletely glycosylated membrane glycoprotein, known as the Tn anti‐
gen (GalNAcα1Ser/Thr). Since the anti-Tn antibody is present in most normal human adult
sera, patients with Tn syndrome display anemia, leucopenia, and thrombocytopenia [64]. It
has been suggested that the Tn syndrome is associated with somatic mutations in the Cosmc
gene on the X chromosome. Cosmc encodes a molecular chaperone required for the proper
folding and hence full activity of T synthase, which is responsible for adding Gal to the Tn
antigen [65]. The sequence analyses of the T synthase and Cosmc genes in whole blood cells
from individuals with Tn syndrome also showed that mutations were only present in the
Cosmc gene, suggesting that these Cosmc mutations lead to T synthase inactivation as well as
the autoimmune Tn antigen expression in blood cells of all lineages.
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4. Degradation of carbohydrate units of glycoproteins
4.1. Degradation by lysosomal enzymes
Glycoconjugates, including glycoproteins, glycolipids, and proteoglycans, are biosynthe‐
sized intracellularly and incorporated extracellularly by endocytic and phagocytic mecha‐
nisms; they are transported via intracellular trafficking to lysosomes, where they are then
catabolized [66]. Both N- and O-linked oligosaccharides of glycoproteins are ultimately de‐
graded in lysosomes. Lysosomes contain more than 60 distinct acid hydrolases, so-called ly‐
sosomal enzymes, as well as their co-factors, including activators and stabilizing proteins.
Most lysosomal glycosidases are classified as exo-type enzymes acting sequentially at the
non-reducing termini [67] and exhibit their optimal catalytic activity under acidic pH condi‐
tions because of the function of vacuolar ATPase [68]. Some of them can also localize in non-
lysosomal compartments, including early endosomes and cell membrane [69]. In addition, a
group of them interact with other enzymes and activator proteins, thereby enhancing the
catalytic efficiency through direct binding or presenting the substrates [70-72].
The biosynthesis of lysosomal enzymes and their co-factors is controlled by gene expression
[73], posttranslational modifications, and intracellular trafficking [67,74]. Specifically, solu‐
ble matrix enzymes are N-glycosylated in the ER and phosphorylated in the Golgi apparatus
at the sixth position of the terminal mannose residues (M6P), via a 2-step reaction catalyzed
by Golgi-localized phosphotransferase and uncovering enzyme (N-acetylglucosaminidase)
necessary to expose terminal M6P residues. The M6P-carrying enzymes then bind the cati‐
on-dependent mannose 6-phosphate receptor (CD-M6PR) at physiological pH in the Golgi
[67,74]. The enzyme–receptor complex is subsequently transported via late endosomes
(where the enzyme dissociates from the receptor at acidic pH) to lysosomes by vesicle fu‐
sion, whereas CD-M6PR, serving as a shuttle, traffics back to the Golgi apparatus. A small
percentage of lysosomal enzymes are also secreted from the cell. The secreted M6P-carrying
enzymes can bind to the cation-independent M6P/IGFII receptor (CI-M6PR) on the plasma
membrane [67,74]. The extracellular lysosomal enzymes can then be endocytosed via glycan
receptors and delivered to lysosomes, where the captured enzymes exert their normal catab‐
olic functions. Taken together, intracellular and extracellular distributions of lysosomal en‐
zymes are regulated by intracellular trafficking and secretion/capture system.
4.2. Lysosomal multienzyme complex for carbohydrate degradation
A group of lysosomal enzymes form a multienzyme complex to regulate their catalytic ac‐
tivities and turnover for efficient catabolism and stabilization. Lysosomal protective protein/
cathepsin A (EC3.4.16.1; CTSA) is a multifunctional glycoprotein that exhibits not only cata‐
lytic activities but also protective functions [70,75]. CTSA is synthesized as a 452-amino-acid
(54-kDa) precursor zymogen that contains intramolecular disulfide bonds and 2 N-glycans
[70,75,76]. In the endosomal/lysosomal compartment, the precursor undergoes endoproteo‐
lytic processing and is converted to the enzymatically active mature form composed of 32-
and 20-kDa subunits [70,75]. The mature enzyme is active at both acidic and neutral pH and
functions as cathepsin A (acid carboxypeptidase)/neutral deamidase/esterase on a subset of
bioactive peptides, including tachykinins and endothelin-1 [77-79], suggesting its contribu‐
tion to a variety of intracellular and extracellular cell processes [80,81]. As for the protective
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functions of CTSA, it forms a multienzyme complex with lysosomal neuraminidase 1 (EC
3.2.1.18; NEU1) and acid β-galactosidase (EC 3.2.1.23; GLB1) to activate NEU1 and protect
GLB1 from physiological proteolysis [70,75] The association of NEU1 with CTSA, which
probably serves as a molecular chaperone, is particularly crucial for NEU1 neuramindase ac‐
tivity, since the activity is lost in the absence of CTSA, even though GLB1 retains at least 10–
15% of the normal enzymatic activity levels [70,75]. The presence of combined deficiency of
these enzymes and the excessive accumulation of sialyloligosaccharides derived from glyco‐
proteins reveal the importance and contribution of the multienzyme complex to the physio‐
logical degradation of the N- and O-glycans derived from glycoproteins.
5. Disorders of glycoprotein carbohydrates and therapeutic approach
5.1. Lysosomal storage diseases (LSDs) causing metabolic errors of glycoprotein
catabolism
Lysosomal storage diseases (LSDs) are inherited metabolic disorders caused by genetic de‐
fects in the lysosomal enzymes and their cofactors. LSDs result in the excessive accumula‐
tion in lysosomes of undegraded substrates, including oligosaccharides derived from
glycoproteins, glycosphingolipids, and glycosaminoglycans derived from proteoglycans
[66,81]. LSDs comprise more than 40 different disorders, and each incidence is about 1 per
100 thousand births, with differences among disorders and races. The clinical manifestations
of LSDs are quite heterogeneous, but many of them involve neurological disorders.
LSDs that are associated with the accumulation of oligosaccharides derived from glycopro‐
teins include α-mannosidosis [82-84], β-mannosidosis [82,83], fucosidosis [82-84], sialidosis
[82,85-87], galactosialidosis [70,75], etc. (Table 1). In this chapter, we will focus on sialidosis and
galactosialidosis, both of which are associated with NEU1 deficiency and characterized by the
accumulation of sialylololigosaccharides and lead to heterogeneous clinical manifestations.
Diseases Responsible enzymes Responsible genes References
Fucosidosis α-Fucosidase FUCA1 [82,83]
α-Mannosidosis α-Mannosidase MAN2B1 [82,83]
β-Mannosidosis β-Mannosidase MANBA [82,83]
Sialidosis Lysosomal sialidase (Neuraminidase 1) NEU1 [82,85-87]
Galactosialidosis Protective protein/cathepsinA* CTSA [70,75,85,88]
Aspartylglucosaminuria Aspartylglucosaminidase AGA [66]
Schindler disease / Kanzaki
disease α-N-Acetylgalactosaminidase NAGA [66]
Table 1. Lysosomal storage diseases (LSDs) caused by the defect in glycoprotein catabolism. *The defect of
protective protein/cathepsin A causes the combined deficiencies of lysosomal sialidase (NEU1) and acid β-
galacosidase (GLB1).
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5.1.1. Sialidosis (MIM 256550)
Sialidosis is an autosomal recessive, lysosomal neuraminidase 1 (NEU1; 6p21) deficiency
[82,89]. NEU1 normally cleaves terminal α2 → 3 and α2 → 6 sialyl linkages of several oligo‐
saccharides and glycopeptides and was found increased in tissues and fluids of affected pa‐
tients. A 1.9-kb cDNA containing an open reading frame of 1,245 nucleotides in size is
predicted to code for a protein that is 415 amino acids long. Distinct from other human neu‐
raminidases (including cytoplasmic NEU2, plasma membrane NEU3, and mitochondrial/
lysosomal NEU4), NEU1 needs to form a complex with CTSA and GLB1 to be catalytically
active, as described above [70,75]. Type I sialidosis, the milder form, is characterized by the
development of ocular cherry-red spots and generalized myoclonus in the second or third
decade of life. Additional manifestations, reported in more than 50% of patients, include
seizures, hyperreflexia, and ataxia [86,87]. Type II sialidosis is distinguished from the Type I
milder form by the early onset of a progressive, rather severe [82,86,87] mucopolysacchari‐
dosis-like phenotype with visceromegaly, dysostosis multiplex, and mental retardation. It
has also been suggested that the residual NEU1 activities in the affected patients in relation
to the kinds of identified missense mutations may be responsible for determining the clinical
phenotypes (milder Type I and severe Type II) of the patients [82,86,87].
5.1.2. Galactosialidosis (MIM 256540)
Galactosialidosis is an autosomal recessive deficiency in the lysosomal protective protein/cathe‐
psin A gene (CTSA; 20q13.2) [75,85]. This disorder is characterized by combined deficiency
of its acid carboxypeptidase/neutral deamidase as well as GLB1 and NEU1, due to the defect
of multienzyme complex formation. Multiple deficiencies arise because CTSA needs to
physiologically associate with NEU1 and GLB1 and form a high-molecular-weight multien‐
zyme complex to activate NEU1 and protect GLB1 from proteolytic degradation, as descri‐
bed above [70,85,88]. All patients exhibit clinical manifestations that are typical of a
lysosomal disorder, such as coarse facies, cherry-red spots, vertebral changes, foam cells in
the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes have been rec‐
ognized. First, the early infantile form is associated with fetal hydrops, edema, ascites, vis‐
ceromegaly, skeletal dysplasia, and early death. Second, the late infantile type is
characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and rare
occurrence of neurologic signs. Third, the juvenile/adult form is characterized by myoclo‐
nus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of viscero‐
megaly, and long survival. The majority of patients belonging to the juvenile/adult group
was reported Japanese origin.
5.1.3. Molecular therapy for LSDs
Several therapeutic approaches have been developed and clinically applied to LSDs [90], in‐
cluding bone marrow transplantation (BMT), enzyme replacement therapy (ERT), gene ther‐
apy (GT), and substrate reduction therapy (SRT). BMT, ERT, and ex vivo GT utilize
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hematopoietic cells transduced with the cDNA of human lysosomal enzymes, which is
based on the findings that normal lysosomal enzymes secreted from the donor cells or exo‐
genously administered can be endocytosed via glycan receptors. These receptors include
mannose receptors that recognize terminal mannose residues [91] and CI-M6PR [74], as de‐
scribed above, that are delivered to the lysosomes where the captured enzymes can exhibit
their normal catabolic functions (cross-correction). However, BMT and ex vivo GT have sev‐
eral disadvantages, including high morbidity and mortality, as well as incomplete responses
to therapy depending on the clinical phenotypes. On the other hand, the intravenous ERT
utilizes recombinant human lysosomal enzymes produced by mammalian cell lines (Chi‐
nese hamster ovary (CHO) and human HT1080) stably expressing their cDNA and has been
found to be the most effective treatment for several LSDs involving visceral symptoms, in‐
cluding type 1 Gaucher disease [92], mucopolysaccharidosis (MPS) type I [93], type II [94],
and type VI [95], Fabry [96], and Pompe diseases [97]. However, the intravenous ERT also
has several disadvantages including long-term therapy, production of neutralizing antibod‐
ies [98], high cost, and little effectiveness to LSDs involving central nervous system (CNS)
symptoms due to the blood-brain barrier (BBB). Clinical trials of the intrathecal ERT are be‐
ing carried out for treating MPS type I [99], II, and IIIB.
GT has advantages such as a long-lasting treatment with a single administration utilizing re‐
combinant viral gene transfer vectors, [100-103] including retrovirus, adenovirus, herpes
simplex virus, adeno-associated virus (AAV), and lentiviruses, albeit with its own attendant
concerns, such as low levels and persistence of expression, as well as insertional mutagene‐
sis resulting in neoplasia.
Alternatively, SRT based on prevention of the biosynthesis of natural substrates by utilizing
synthetic substrate analogs, has been clinically applied [90,104,105], even though its utility is
limited by side effects, continuous administration, and high cost.
In contrast, no definitive treatment is clinically available for LSDs involving glycoprotein ca‐
tabolism, even though preclinical experiments with animal models have been performed.
Heterologous BMT in a ferine α-mannosidosis model caused by a 4-bp deletion in the feline
MAN2B1 gene showed significant therapeutic effects on the CNS symptoms, in which case
the therapy began when mild clinical signs were present [106]. Brain-directed GT using the
AAV vector for 8-week-old cats with α-mannosidosis also showed remarkable restoration of
brain α-mannosidase activity, improvement in myelination abnormalities, reduction of sub‐
strates in the neurons, neurological signs, and prolonged life span [107]. A canine α-fucosi‐
dosis model caused by a 14-bp deletion in the canine FUCA1 gene has also been treated with
heterologous BMT, the administration of which at an early age demonstrated efficacy for
CNS symptoms [108].
Moreover, a murine galactosialidosis model (Ctsa-/-) was treated with cell-type specific ex
vivo GT [109,110] by using donor bone marrow-derived cells that were transduced with
murine-based retroviral vectors, containing human CTSA cDNA under the control of the
promoter of murine monocyte/macrophage-specific colony-stimulating factor-1 receptor.
Transgenic macrophages infiltrated and resided in all organs, and correction due to the se‐
creted CTSA was observed not only in hematopoietic tissues but also in nonhematopoietic
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organs, including the CNS. Systemic GT for Ctsa-/- mice was also performed using a liver-
tropic recombinant AAV-2/8 vector [111]. Despite the restricted expression of CTSA in the
liver, dose-dependent and widespread correction of the disease phenotype in other systemic
organs, serum, and urine, was observed, suggesting the protein-mediated mechanism of
cross-correction.
Several approaches used to develop ERT for sialidosis and galactosialidosis have been chal‐
lenged. The murine sialidosis model was treated with a short-term, high-dose ERT using ba‐
culovirus-derived recombinant Neu1 [112]. The terminal mannosylated Neu1 taken up by
resident macrophages in visceral organs restored the Neu1 activity and reduced the accu‐
mulation of sialyl substrates in lysosomes; however, mice developed a severe immune re‐
sponse towards the exogenous Neu1 as a side effect [112]. Recently, Itoh et al succeeded in
producing a transgenic silkworm strain that overexpresses mature human CTSA in the mid‐
dle silk glands (unpublished data). Purified mature CTSA carrying the human-like, high-
mannose-type oligosaccharides lacking insect-specific carbohydrate moiety was taken up by
murine monocytic cell lines via MR to be delivered to lysosomes. The conjugate between
CTSA and a cell-penetrating peptide was also efficiently incorporated into the fibroblasts
derived from galactosialidosis patients to be delivered to lysosomes and thereafter reduced
the accumulation of sialyloligosaccharides in the cells. The novel recombinant human CTSA
could be applied as a low-antigenic enzyme to intrathecal ERT for treating galactosialidosis
patients exhibiting neurological symptoms.
6. Conclusions
Carbohydrates are very important molecules not only as energy sources but also for a wide
variety of cellular functions, ranging from cell-cell interaction to immunity (1). Examples of
glycosylation disorders described above clearly demonstrate that addition of carbohydrates
to proteins is crucial for maintaining normal cellular physiology and that glycosylation dis‐
orders affect various cellular activities. The sugar chains, although not the direct gene prod‐
ucts, contain essential information for the proper cellular function. The information,
encoded by carbohydrate structures, is regarded as the sugar codes and is deciphered by a
collection of carbohydrate-recognizing molecules, such as selectins and galectins [113,114].
In other words, glycosylation disorders can be considered as failures in interpreting the sug‐
ar codes. Due to their structural similarity and heterogeneity, carbohydrates are the most
difficult molecules to study with the methods commonly used for nucleic acids and pro‐
teins. While the structure-function relationship of carbohydrates have remained unclear for
a long time, the recent progress in separation, mass spectrometry, and genome-wide associa‐
tion studies of carbohydrates has been bringing information more rapidly than ev‐
er[115,116]. We expect that rapidly increasing knowledge of glycan structures and functions
will help not only understand the importance of glycosylation in biology and diseases but
also, in the near future, exploit the way to treat glycosylation-related diseases.
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